1. Vertex Pharmaceuticals, but focused on specific genetic mutations like those found in systemic mastocytosis and certain gastrointestinal stromal tumors.

2. A precision-focused Novartis, developing highly targeted drugs for specific genetic mutations in diseases like systemic mastocytosis.

• CGT9486 (bezuclastinib): A selective tyrosine kinase inhibitor designed to treat systemic mastocytosis and advanced gastrointestinal stromal tumors by inhibiting specific KIT mutations.

Company Name (Symbol): Cogent Biosciences (COGT)

Cogent Biosciences (COGT) is a clinical-stage biotechnology company. At its current stage of operations, the company is primarily focused on the research, development, and clinical trials of its lead product candidate, CGT9486, and other pipeline therapies. As such, it does not currently have commercialized products available for sale and therefore does not have "major customers" in the traditional sense of companies or individuals purchasing its products.

Given its business model, if its product candidates successfully complete clinical development and receive regulatory approval, Cogent Biosciences would primarily sell to other companies within the healthcare ecosystem. These potential future customer categories would include:

• Healthcare Providers: Hospitals, clinics, and other medical institutions that would administer or prescribe the company's approved therapies to patients.
• Pharmaceutical Distributors & Pharmacies: Wholesalers, specialty pharmacies, and retail pharmacies responsible for the distribution and dispensing of prescription medications.
• Licensing or Commercialization Partners: Other pharmaceutical or biotechnology companies with whom Cogent Biosciences might partner for co-development, licensing, or commercialization of its products in specific markets or therapeutic areas.

Andrew Robbins, Chief Executive Officer and President

Mr. Robbins was appointed CEO of Cogent Biosciences in October 2020. He brings over 20 years of extensive commercial, development, and strategic leadership experience within the pharmaceutical industry, with a particular focus on oncology and hematology products. Before joining Cogent, he served as Chief Operating Officer at Array Biopharma until its acquisition by Pfizer in 2019. At Array, he was instrumental in leading the sales, marketing, manufacturing, and corporate strategy teams, which culminated in the successful commercialization of Mektovi and Braftovi for BRAF mutant metastatic melanoma. Earlier in his career, Mr. Robbins held management positions at Hospira, Inc. and Pfizer Inc. as part of its Oncology business unit. He currently serves on the Board of Directors for Turmeric Acquisition Corporation.

John Green, Chief Financial Officer

Mr. Green has served as the Chief Financial Officer and Principal Accounting Officer of Cogent Biosciences since July 2020. Prior to this role, he was the Vice President of Finance and Controller at the company (then Unum Therapeutics Inc.) from April 2018 to June 2020. He possesses nearly 20 years of strategic finance and accounting experience, with approximately half of that time spent in the biotechnology industry across both public and private companies. His previous roles include Principal Accounting Officer at Merrimack Pharmaceuticals from March 2017 to June 2018, where he led the finance team through a $1.025 billion asset sale of a commercial pancreatic cancer drug and subsequent de-commercialization. He also served as Controller at Fractyl Laboratories Inc. from November 2015 to March 2017 and Director of Accounting at Dicerna Pharmaceuticals, Inc. from June 2014 to November 2015.

Cole Pinnow, Chief Commercial Officer

Mr. Pinnow was appointed Chief Commercial Officer in May 2024. He is a recognized leader in the biopharmaceutical industry with a strong background in commercial strategy and multiple successful product launches. At Cogent, he is responsible for building and leading the commercial team, including sales, marketing, access, and commercial operations, with a key focus on preparing for the potential commercial launch of bezuclastinib. He joined Cogent from Pfizer, where his roles included President and Managing Director of Pfizer Canada and Global Franchise Lead, Genitourinary and Breast Cancer Business, overseeing a $5 billion innovative cancer portfolio.

Jessica Sachs, MD, Chief Medical Officer

Dr. Sachs serves as the Chief Medical Officer at Cogent Biosciences. She is a key member of the leadership team responsible for guiding the strategic vision and operational execution of the company's clinical development programs.

John Robinson, PhD, Chief Scientific Officer

Dr. Robinson is the Chief Scientific Officer at Cogent Biosciences. He leads the Cogent Research Team, which focuses on discovering and developing novel small molecule therapies for rare, genetically driven diseases.

Cogent Biosciences (NASDAQ: COGT) faces several key risks as it progresses its lead product candidate, bezuclastinib, through clinical development and towards commercialization.

1. Dependence on Regulatory Approval and Commercialization of Bezuclastinib

Cogent Biosciences' future success and financial performance are heavily reliant on the successful regulatory approval and subsequent commercialization of its lead product candidate, bezuclastinib. The company's entire investment thesis hinges on bezuclastinib's ability to justify years of significant investment. While bezuclastinib has shown positive results in pivotal trials for systemic mastocytosis and gastrointestinal stromal tumors (GIST), and New Drug Applications (NDAs) are being submitted or are on track for submission, regulatory approval is never guaranteed. Any setbacks in regulatory approval or delays in commercialization could significantly impact the company.

2. Need for Additional Financing and Risk of Shareholder Dilution

The development and commercialization of bezuclastinib, along with other potential product candidates, require substantial capital investment. Cogent Biosciences currently operates without revenue and has reported significant net losses, including $328.94 million in 2025. The company's ability to secure additional financing, manage its expenses, and eventually generate revenue is critical for its sustained operations. There is an ongoing risk of further shareholder dilution, evidenced by past dilution and the filing of a shelf registration to provide financial flexibility.

3. Intense Competition

Cogent Biosciences operates within a highly competitive biotechnology and pharmaceutical landscape. The company faces competition from both established pharmaceutical companies with greater resources and emerging biotechs, which could challenge its ability to secure a strong market position for bezuclastinib. In systemic mastocytosis, approved therapies include avapritinib from Blueprint Medicines and midostaurin and imatinib from Novartis AG. For GIST, Cogent will compete with existing later-line tyrosine kinase inhibitors such as Bayer's Stivarga, Deciphera's Qinlock, and Blueprint's Ayvakit. Competitors with more rapid regulatory approvals or substantial resources could pose significant threats to Cogent's commercial opportunities.

Cogent Biosciences (COGT) focuses on developing precision therapies for genetically defined diseases, with its lead product candidate, CGT9486 (bezuclastinib), targeting systemic mastocytosis (SM) and gastrointestinal stromal tumors (GIST). The addressable markets for these main products are substantial, with variations depending on the specific region and forecast period.

Systemic Mastocytosis (SM)

• The global systemic mastocytosis treatment market is projected to grow from approximately 1.2 billion USD in 2024 to 1.9 billion USD by 2030.
• For the United States, the systemic mastocytosis market is expected to increase from an estimated 0.36 billion USD in 2024 to 0.54 billion USD by 2030.
• Another report indicates that the global systemic mastocytosis treatment market size is anticipated to reach 1.22 billion USD by 2033.
• Cogent Biosciences estimates the market opportunity for Advanced Systemic Mastocytosis (AdvSM) to be approximately 500 million USD, while the market for Non-Advanced Systemic Mastocytosis (NonAdvSM) could be around 3 billion USD.

Gastrointestinal Stromal Tumors (GIST)

• The global gastrointestinal stromal tumor market size was valued at 1.28 billion USD in 2024 and is projected to reach 2.15 billion USD by 2032.
• Another estimate places the global gastrointestinal stromal tumor treatment market at 1.5 billion USD in 2024, with a forecast to grow to 3.2 billion USD by 2034.
• In the 7 Major Markets (7MM), which include the United States, EU4 countries (Germany, Italy, France, and Spain), the United Kingdom, and Japan, the GIST market size was approximately 450 million USD in 2023. The United States alone accounted for about 69% of this 7MM market size in 2023, with the U.S. market reaching 561.8 million USD in 2024.
• Cogent Biosciences estimates the GIST market to be over 4 billion USD.

Cogent Biosciences (COGT) is expected to drive future revenue growth over the next 2-3 years through the anticipated commercialization and market penetration of its lead product candidate, bezuclastinib (CGT9486), across multiple indications. The key drivers include:

1. Launch and Uptake of Bezuclastinib in Non-Advanced Systemic Mastocytosis (Non-AdvSM): Cogent Biosciences submitted a New Drug Application (NDA) for bezuclastinib in non-advanced systemic mastocytosis in December 2025, with anticipated FDA acceptance in February 2026 and a potential commercial launch in the second half of 2026. The company has reported positive pivotal data from the SUMMIT trial, demonstrating significant improvements in symptoms and biomarkers. The U.S. moderate-to-severe non-advanced systemic mastocytosis population is estimated to be around 6,000–8,000 patients, with a total addressable market in Western countries projected to be approximately $3.5–$4 billion.
2. Launch and Uptake of Bezuclastinib in Second-Line Gastrointestinal Stromal Tumors (GIST): The company plans to submit an NDA for bezuclastinib in GIST in April 2026, with potential commercialization by early 2027. Positive Phase 3 results from the PEAK study in imatinib-resistant or intolerant GIST patients, where bezuclastinib in combination with sunitinib significantly improved progression-free survival and objective response rates, position it to potentially become the new standard of care and the first new therapy for second-line GIST in over 20 years. Analysts have indicated a multibillion-dollar market opportunity and blockbuster revenue projections for this indication.
3. Launch and Uptake of Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM): Cogent Biosciences is on track to submit an NDA for bezuclastinib in advanced systemic mastocytosis in the first half of 2026, with potential commercialization following FDA review, targeting full commercialization by early 2027. The APEX trial in AdvSM has also shown promising objective response rates.
4. Market Share Capture Driven by Bezuclastinib's Differentiated Profile: Bezuclastinib's strong KIT selectivity and lack of central nervous system (CNS) penetration are highlighted as key differentiating factors, which could lead to superior symptom and biomarker responses and a better safety profile compared to existing treatments. This differentiated profile is expected to enable bezuclastinib to capture a substantial market share across its approved indications, driving significant revenue growth as it becomes a competitive option for physicians and patients.

Share Issuance

• In November 2025, Cogent Biosciences generated approximately $475.3 million in net proceeds from concurrent public offerings of common stock and 1.625% convertible senior notes due 2031.
• An upsized underwritten public offering in July 2025 of 25,555,556 shares of common stock at $9.00 per share, including the underwriters' option exercise, yielded net proceeds of $215.8 million.
• The company also raised $39 million (in Q3 2025) and $24.3 million (in Q1 2025) through targeted share sales via its at-the-market (ATM) facility.

Inbound Investments

• In June 2025, Cogent Biosciences secured a debt financing facility of up to $400 million with SLR Capital Partners, LLC, with an initial $50 million drawn at closing.

Capital Expenditures

• Cogent Biosciences reported capital expenditures of $1.72 million for the full year 2025.
• Capital expenditures for the full year 2024 were $0.55 million.
• The company's research and development (R&D) expenses, a significant area of investment for a biotechnology company, totaled $269.8 million in 2025 and $232.7 million in 2024, primarily supporting clinical trials for bezuclastinib and other programs.